サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1714335

関節内補充療法市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、最終用途別、地域別、競合市場別、2020-2030F

Viscosupplementation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product Type, By End Use By Region & Competition, 2020-2030F

出版日
ページ情報
英文 184 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

関節内補充療法市場- 世界の産業規模、シェア、動向、機会、予測、製品タイプ別、最終用途別、地域別、競合市場別、2020-2030F
出版日: 2025年04月25日
発行: TechSci Research
ページ情報: 英文 184 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

関節内補充療法市場は、2024年に47億6,000万米ドルと評価され、2030年には76億8,000万米ドルに達し、CAGR 8.25％で成長すると予測されています。

この成長は主に、特に高齢化社会における変形性関節症やその他の筋骨格系障害の発生率の増加に起因しています。ヒアルロン酸ベースの溶液を関節に注入する関節内補充療法は、外科的介入に代わる低侵襲性を提供し、可動性を高めて関節痛を軽減します。この市場は、製品開発の進展と、変形性膝関節症だけでなく他の関節への応用拡大によってさらに支えられています。スポーツに関連したケガの増加や、手術以外の治療法への世界のシフトも需要を後押ししています。しかし、高い治療費と一貫性のない保険償還政策が、一部の地域での普及の障壁となっています。

市場概要
予測期間 2026-2030
市場規模：2024年 47億6,000万米ドル
市場規模：2030年 76億8,000万米ドル
CAGR：2025年～2030年 8.25%
急成長セグメント スリーインジェクション
最大市場 アジア太平洋

市場促進要因

高齢化人口の増加

主な市場課題

高い治療費

主要市場動向

生体適合性ヒアルロン酸（HA）誘導体

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 関節内補充療法市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 製品タイプ別（単発噴射、3回噴射、5回噴射）
    • 用途別（病院、整形外科クリニック/ASC）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の関節内補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の関節内補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の関節内補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の関節内補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの関節内補充療法市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 PESTEL分析

第14章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第15章 世界の関節内補充療法市場：SWOT分析

第16章 競合情勢

  • Sanofi SA
  • Seikagaku Corporation
  • Smith & Nephew PLC.
  • Lifecore Biomedical, LLC.
  • Fidia Farmaceutici S.p.A
  • F.Hoffmann-La Roche Ltd.
  • LG Life Sciences Ltd.
  • Ferring Pharmaceutical B.V.
  • Zimmer Biomet Holdings Inc
  • Anika Therapeutics, Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

目次
Product Code: 16098

The Viscosupplementation Market was valued at USD 4.76 billion in 2024 and is projected to reach USD 7.68 billion by 2030, growing at a CAGR of 8.25%. This growth is primarily attributed to the increasing incidence of osteoarthritis and other musculoskeletal disorders, particularly among the aging population. Viscosupplementation, which involves injecting hyaluronic acid-based solutions into joints, offers a minimally invasive alternative to surgical interventions, enhancing mobility and reducing joint pain. The market is further supported by advancements in product development and the broadening of applications beyond knee osteoarthritis to other joints. Rising cases of sports-related injuries and the global shift toward non-surgical treatment options have also fueled demand. However, high treatment costs and inconsistent insurance reimbursement policies continue to pose barriers to widespread adoption in some regions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.76 Billion
Market Size 2030USD 7.68 Billion
CAGR 2025-20308.25%
Fastest Growing SegmentThree-injection
Largest MarketAsia Pacific

Key Market Drivers

Rising Aging Population

One of the most influential factors driving growth in the global viscosupplementation market is the rising aging population. According to the United Nations Department of Economic and Social Affairs, the global population aged 60 and above is projected to reach 2.1 billion by 2050, up from 1.2 billion in 2024. This age group is highly susceptible to osteoarthritis (OA), a major condition treated with viscosupplementation. Statistics show that 43% of individuals with OA are aged 65 or older, while 88% are aged 45 or older. The 55-64 age group reports the highest annual incidence of knee OA, positioning them as a key demographic for viscosupplementation therapy. As this segment of the population grows, so does the demand for effective, non-surgical joint treatments to improve mobility and quality of life. This demographic trend supports the long-term expansion of the viscosupplementation market.

Key Market Challenges

High Treatment Cost

The elevated cost of viscosupplementation treatments presents a major challenge for market expansion. These treatments often require multiple injections over time, especially for chronic conditions like osteoarthritis, leading to recurring expenses. This becomes a financial burden for patients lacking sufficient insurance coverage and creates reimbursement hurdles for healthcare providers. In some healthcare systems, limited insurance policies or delays in reimbursement further deter the adoption of these therapies. The high cost may prompt patients to pursue more affordable alternatives such as medications or physical therapy. To mitigate this issue, the market must focus on enhancing cost-efficiency through pricing strategies, improved insurance coverage, and patient education regarding the long-term benefits of viscosupplementation over other management options for joint pain.

Key Market Trends

Biocompatible Hyaluronic Acid (HA) Derivatives

A notable trend in the Viscosupplementation Market is the increasing development and use of biocompatible hyaluronic acid (HA) derivatives. These derivatives are engineered to replicate the properties of natural HA more closely, offering longer-lasting joint lubrication and improved pain relief. By minimizing injection frequency and maximizing therapeutic outcomes, these products enhance patient compliance and comfort. Additionally, their improved safety profile-due to a lower likelihood of adverse reactions-makes them more favorable for long-term use. Patients benefit from extended relief and reduced joint inflammation, resulting in better mobility and higher satisfaction. Manufacturers are investing in research to develop advanced HA derivatives that offer more effective, durable, and convenient treatment options. This trend is expected to reshape osteoarthritis care by providing innovative solutions that improve patient outcomes and treatment experiences.

Key Market Players

  • Sanofi SA
  • Seikagaku Corporation
  • Smith & Nephew PLC.
  • Lifecore Biomedical, LLC.
  • Fidia Farmaceutici S.p.A
  • F. Hoffmann-La Roche Ltd.
  • LG Life Sciences Ltd.
  • Ferring Pharmaceutical B.V.
  • Zimmer Biomet Holdings Inc
  • Anika Therapeutics, Inc.

Report Scope:

In this report, the Global Viscosupplementation Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Viscosupplementation Market, By Product Type:

  • Single Injection
  • Three Injection
  • Five Injection

Viscosupplementation Market, By End User:

  • Hospitals
  • Orthopedic Clinics/ASCs

Viscosupplementation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Viscosupplementation Market.

Available Customizations:

Global Viscosupplementation market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Viscosupplementation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product Type (Single Injection, Three Injection, Five Injection)
    • 5.2.2. By End Use (Hospitals, Orthopedic Clinics/ASCs)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Viscosupplementation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Viscosupplementation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Viscosupplementation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Viscosupplementation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product Type
        • 6.3.3.2.2. By End Use

7. Europe Viscosupplementation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Viscosupplementation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. United Kingdom Viscosupplementation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. Italy Viscosupplementation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. France Viscosupplementation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Viscosupplementation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product Type
        • 7.3.5.2.2. By End Use

8. Asia-Pacific Viscosupplementation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Viscosupplementation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Viscosupplementation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Viscosupplementation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Viscosupplementation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Viscosupplementation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product Type
        • 8.3.5.2.2. By End Use

9. South America Viscosupplementation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Viscosupplementation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Viscosupplementation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Viscosupplementation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product Type
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Viscosupplementation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product Type
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Viscosupplementation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Viscosupplementation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Viscosupplementation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product Type
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Global Viscosupplementation Market: SWOT Analysis

16. Competitive Landscape

  • 16.1. Sanofi SA
    • 16.1.1. Business Overview
    • 16.1.2. Product & Service Offerings
    • 16.1.3. Recent Developments
    • 16.1.4. Financials (If Listed)
    • 16.1.5. Key Personnel
    • 16.1.6. SWOT Analysis
  • 16.2. Seikagaku Corporation
  • 16.3. Smith & Nephew PLC.
  • 16.4. Lifecore Biomedical, LLC.
  • 16.5. Fidia Farmaceutici S.p.A
  • 16.6. F.Hoffmann-La Roche Ltd.
  • 16.7. LG Life Sciences Ltd.
  • 16.8. Ferring Pharmaceutical B.V.
  • 16.9. Zimmer Biomet Holdings Inc
  • 16.10.Anika Therapeutics, Inc.

17. Strategic Recommendations

18. About Us & Disclaimer